Zhang Guowei, Wang Huijuan, Zhang Mina, Li Peng, Ma Zhiyong
Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Zhongguo Fei Ai Za Zhi. 2015 Sep 20;18(9):587-91. doi: 10.3779/j.issn.1009-3419.2015.09.10.
In recent years, along with rapid development of targeted therapy in non-small cell lung cancer, traditional chemotherapy get less and less attention. Yet it still can not be ignored in the current that how to locate and use traditional chemotherapy so patients could derive maximum benefit. For this purpose, through the literature review and analysis, we point out there are still many traditional chemotherapy irreplaceable places whatever patients' driver gene status. And there are some new treatment modalities of traditional chemotherapy which have been developed to further improve patients' survival. At the same time, through exposition of predictive bio-markers development in chemotherapy, we pointed out that the future of traditional chemotherapy must be part of "targeted therapy".
近年来,随着非小细胞肺癌靶向治疗的迅速发展,传统化疗受到的关注越来越少。然而,在当前如何定位和应用传统化疗以使患者获得最大益处的问题仍不容忽视。为此,通过文献回顾与分析,我们指出无论患者的驱动基因状态如何,传统化疗仍有许多不可替代之处。并且已经开发出一些传统化疗的新治疗模式以进一步提高患者生存率。同时,通过阐述化疗中预测性生物标志物的发展,我们指出传统化疗的未来必定是“靶向治疗”的一部分。